Archive

Rebel Category: REBEL EM

ISAR-REACT 5 Trial: Ticagrelor vs Prasugrel in ACS

Background: In patients presenting to the ED with acute coronary syndrome (ACS), dual antiplatelet therapy is the current standard treatment.  This typically consists of aspirin and an adenosine diphosphate receptor antagonist.  It is fairly well understood that prasugrel and ticagrelor ...

Read More
Cardiovascular

The RECOVERY Trial: Dexamethasone for COVID-19?

Background: We have been in need of a sign of hope in the fight against SARS-CoV-2 as it runs from city to city overwhelming health systems.  The majority of patients will be either asymptomatic or have only mild disease.  These ...

Read More
Infectious Disease

Factor Xa Inhibitor Related ICH & PCCs

Background: Factor Xa inhibitors have gained more use over the past several years due to the ease of administration and easier monitoring. However, bleeding, namely intracranial hemorrhage (ICH) is still a risk and the lack of a proven antidote is ...

Read More
Hematology and Oncology

Fluid Administration in End-Stage Renal Disease for Severe Sepsis and Septic Shock by Shyam Murali, MD

Background: In end-stage renal disease (ESRD) patients on hemodialysis (HD), infection is the second most common cause of mortality after cardiovascular disease (Sarnik 2000). Because of the systemic inflammation and increased capillary permeability, septic patients are at significant risk for fluid ...

Read More
Endocrine, Metabolic, Fluid, and ElectrolytesInfectious DiseaseResuscitation

Hydroxychloroquine is Ineffective for Post-Exposure Prophylaxis

Background: Despite the initial excitement around the use of chloroquine (CQ) and hydroxychloroquine (HCQ), there is mounting evidence that neither drug is effective in COVID-19 treatment. Laboratory studies have shown antiviral and immunomodulatory properties in vitro but these have not ...

Read More
Infectious Disease
Showing Slide 1 of 6
rebelSWAG-lightbg
gsep-logo-1

Sponsored